Meningitis: all 268 studies

Page 1 of 3. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation TrialNot yet recruitingNCT07922226Phase 2/3
• THiamine for Recovery In Vulnerable Early-life InfectionsNot yet recruitingNCT07868679Phase 2
• Group-based Emotional Awareness and Expression Therapy to Support Recovery After Acquired Brain Injury: A Clinical Development and Evaluation StudyRecruitingNCT07852936Not applicable
• Clinical Characteristics and Prognostic Factors in Patients With Meningitis at Sohag Governorate.Not yet recruitingNCT07768982
• Immune-Mitochondrial Correction in Military RecruitsNot yet recruitingNCT07622147Not applicable
• Recovery Trajectory for Coma and Disorders of ConsciousnessRecruitingNCT07614074
• Hemorrhage Elimination During Lumbar Puncture Using Ultrasound Measurements (HELPUS)RecruitingNCT07612644Not applicable
• Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.RecruitingNCT07432113Not applicable
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
• Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral PathologiesRecruitingNCT07332234
• Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural Lesions: Superior Efficacy, Critical Impact of Surgical Timing, and Pathogenic Bacteria as Risk Factors for ProgressionNot yet recruitingNCT07320599
• BPaLMZ for TB MeningitisRecruitingNCT07227779Phase 2
• Evolving Diagnostic Approaches to Undocumented Lymphocytic Meningitis and MeningoencephalitisEnrolling by invitationNCT07186881
• Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children MeningitisRecruitingNCT07062445
• Acute Treatment and Long-term Assessment of Adult Infectious MeningitisRecruitingNCT07027475
• Causes of Secondary and Prolonged Fever During Treatment of Bacterial Meningitis and Viral EncephalitisNot yet recruitingNCT06971133
• Neonatal Comfort Seat Allowing Safe Lumbar Puncture and Minimizing Failure: a Randomized Controlled TrialNot yet recruitingNCT06811428Not applicable
• Phase II Clinical Study of Contezolid for the Treatment of Tuberculous MeningitisEnrolling by invitationNCT06811025Phase 1/2
• Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children.RecruitingNCT06584864Not applicable
• Adjunctive Doxycycline for Central Nervous System TuberculosisRecruitingNCT06446245Phase 2
• Improving Diagnosis and Prediction of Outcome in Patients With Severe Disorders of ConsciousnessRecruitingNCT06283901
• Meningitis: Burden, Causes, Screening and Prevention in Rural Northern UgandaRecruitingNCT05496673Not applicable
• Aciclovir Versus Placebo for HSV-2 MeningitisNot yet recruitingNCT05452928Phase 4
• Regulating Emotions and Behaviors After Brain InjuryRecruitingNCT05393492Not applicable
• Establishment of Prevention and Control System of Central Nervous System InfectionNot yet recruitingNCT04722328
• National Bacterial Meningitis Study in Children and NewbornsRecruitingNCT04664569
• Central Nervous System Infections in DenmarkRecruitingNCT03418441
• Lebanese Interhospital Pneumococcal Surveillance ProgramRecruitingNCT00901602
• A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)CompletedNCT06995430Phase 3Results posted
• Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate VaccineCompletedNCT05093829Phase 3Results posted
• Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedNCT04502693Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of AgeCompletedNCT04318548Phase 3Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of AgeCompletedNCT03652610Phase 2Results posted
• Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedNCT03621670Phase 3Results posted
• Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 YearsCompletedNCT03587207Phase 2Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of AgeCompletedNCT03433482Phase 2Results posted
• Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT03205358Phase 2Results posted
• Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompletedNCT03077438Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY VaccinationCompletedNCT02986854Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompletedNCT02955797Phase 3Results posted
• Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in AdolescentsCompletedNCT02946385Phase 2Results posted
• Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory CohortCompletedNCT02910037Not applicableResults posted
• Hypovitaminosis D in Neurocritical PatientsCompletedNCT02881957Phase 2/3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompletedNCT02842866Phase 3Results posted
• Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02842853Phase 3Results posted
• Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02752906Phase 3Results posted
• Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in VietnamCompletedNCT02640404Phase 2Results posted
• Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years EarlierCompletedNCT02633787Phase 4Results posted
• Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult SubjectsCompletedNCT02591290Phase 4Results posted
• A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsCompletedNCT02447432Phase 3Results posted
• Combined Study - Phase 3b MenB Long Term Persistence in AdolescentsCompletedNCT02446743Phase 3Results posted
• A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate VaccineCompletedNCT02374450Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 2Results posted
• Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.CompletedNCT02173704Phase 3Results posted
• Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.CompletedNCT02141516Phase 3Results posted
• Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese ChildrenCompletedNCT02139228Phase 3Results posted
• Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy InfantsCompletedNCT02106390Phase 3Results posted
• Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.CompletedNCT01973218Phase 3Results posted
• Auditory Brainstem Implantation in Young ChildrenCompletedNCT01904448Not applicableResults posted
• Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate VaccineCompletedNCT01897402Phase 2Results posted
• Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian FederationCompletedNCT01890759Phase 3Results posted
• Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster DoseCompletedNCT01823536Phase 4Results posted
• Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal MeningitisCompletedNCT01802385Phase 3Results posted
• Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompletedNCT01732627Phase 2Results posted
• Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaCompletedNCT01725217Phase 3Results posted
• Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to ChildrenCompletedNCT01689155Results posted
• Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
• Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South KoreaCompletedNCT01642589Phase 3Results posted
• Lumbar Punctures in Neonates: Improving Success Rates and Minimizing PainTerminatedNCT01606150Not applicableResults posted
• Rituximab in IgG4-RD: A Phase 1-2 TrialCompletedNCT01584388Phase 1/2Results posted
• Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese SubjectsCompletedNCT01519713Phase 3Results posted
• A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk AdultsCompletedNCT01478347Phase 3Results posted
• Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra VaccineCompletedNCT01442675Phase 2Results posted
• Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersCompletedNCT01434680Phase 2Results posted
• Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in ChildrenCompletedNCT01430611Phase 4Results posted
• A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in AdolescentsCompletedNCT01424644Phase 4Results posted
• Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study VaccinesCompletedNCT01367158Phase 2Results posted
• Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine ImmunizationsCompletedNCT01359449Phase 3Results posted
• Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate VaccineCompletedNCT01345721Phase 3Results posted
• A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.CompletedNCT01323270Phase 2Results posted
• A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaCompletedNCT01274897Phase 3Results posted
• Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the PhilippinesCompletedNCT01270503Phase 4Results posted
• Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial VaccinationCompletedNCT01239043Phase 2Results posted
• Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeCompletedNCT01214837Phase 3Results posted
• Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate VaccineCompletedNCT01148017Phase 3Results posted
• A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in IndiaCompletedNCT01086969Phase 3Results posted
• A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompletedNCT01049035Phase 2Results posted
• Cerebrospinal Fluid Pharmacokinetics of DaptomycinTerminatedNCT01025271Not applicableResults posted
• A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWYCompletedNCT01018732Phase 2Results posted
• Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsCompletedNCT00937521Phase 2Results posted
• Treatment of West Nile Virus With MGAWN1TerminatedNCT00927953Phase 2Results posted
• High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected IndividualsCompletedNCT00885703Phase 1/2Results posted
• Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® VaccineCompletedNCT00862277Results posted
• Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate VaccineCompletedNCT00856297Phase 3Results posted
• Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®CompletedNCT00850603Phase 4Results posted
• Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00806195Phase 3Results posted
• Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in AdolescentsCompletedNCT00777790Phase 2Results posted
• Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccineCompletedNCT00777257Phase 4Results posted
• Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy AdultsTerminatedNCT00772629Phase 2Results posted

← Meningitis overview